用编码恶性疟原虫环子孢子蛋白全长序列的重组痘病毒FP9和改良安卡拉痘苗病毒进行初免-加强免疫的安全性、免疫原性和有效性。
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
作者信息
Walther Michael, Thompson Fiona M, Dunachie Susanna, Keating Sheila, Todryk Stephen, Berthoud Tamara, Andrews Laura, Andersen Rikke F, Moore Anne, Gilbert Sarah C, Poulton Ian, Dubovsky Filip, Tierney Eveline, Correa Simon, Huntcooke Angela, Butcher Geoffrey, Williams Jack, Sinden Robert E, Hill Adrian V S
机构信息
Centre for Clinical Vaccinology & Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, United Kingdom.
出版信息
Infect Immun. 2006 May;74(5):2706-16. doi: 10.1128/IAI.74.5.2706-2716.2006.
Abstract
Heterologous prime-boost immunization with DNA and various recombinant poxviruses encoding malaria antigens is capable of inducing strong cell-mediated immune responses and partial protection in human sporozoite challenges. Here we report a series of trials assessing recombinant fowlpox virus and modified vaccinia virus Ankara encoding the Plasmodium falciparum circumsporozoite protein in various prime-boost combinations, doses, and application routes. For the first time, these vaccines were administered intramuscularly and at doses of up to 5 x 10(8) PFU. Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge.
摘要
用编码疟疾抗原的DNA和各种重组痘病毒进行异源初免-加强免疫能够在人体子孢子攻击试验中诱导强烈的细胞介导免疫反应并提供部分保护。在此，我们报告了一系列试验，评估了重组鸡痘病毒和安卡拉痘病毒，它们编码恶性疟原虫环子孢子蛋白，采用了不同的初免-加强组合、剂量和接种途径。这些疫苗首次通过肌肉注射给药，剂量高达5×10⁸ PFU。含有该抗原的疫苗被证明是安全的，能诱导适度的免疫反应，但在子孢子攻击试验中未显示出有效性证据。
相似文献
1
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.用编码恶性疟原虫环子孢子蛋白全长序列的重组痘病毒FP9和改良安卡拉痘苗病毒进行初免-加强免疫的安全性、免疫原性和有效性。
Infect Immun. 2006 May;74(5):2706-16. doi: 10.1128/IAI.74.5.2706-2716.2006.
2
A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.一种编码血小板反应蛋白相关粘附蛋白而非环子孢子蛋白的DNA初免-修饰安卡拉痘苗病毒加强疫苗，可部分保护未感染过疟疾的健康成年人免受恶性疟原虫子孢子攻击。
Infect Immun. 2006 Oct;74(10):5933-42. doi: 10.1128/IAI.00590-06.
3
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.通过使用重组痘病毒FP9和改良安卡拉痘苗病毒，增强T细胞介导的对人类疟疾攻击的保护作用。
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41. doi: 10.1073/pnas.0406381102. Epub 2005 Mar 21.
4
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.重组鸡痘病毒株FP9和改良安卡拉痘苗病毒疫苗在非免疫志愿者中针对恶性疟原虫肝期疟疾的安全性。
Vaccine. 2006 Apr 5;24(15):3026-34. doi: 10.1016/j.vaccine.2005.10.058. Epub 2006 Feb 2.
5
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.重组改良安卡拉痘苗病毒增强的质粒DNA疫苗在人体内的T细胞免疫原性增强。
Nat Med. 2003 Jun;9(6):729-35. doi: 10.1038/nm881. Epub 2003 May 25.
6
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.对3种高免疫原性的初免-加强免疫方案（包括12个月后的再次加强免疫接种）在冈比亚男性中进行疟疾疫苗接种的1期评估。
J Infect Dis. 2004 Jun 15;189(12):2213-9. doi: 10.1086/421118. Epub 2004 May 24.
7
A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.使用DNA随后接种重组改良安卡拉痘病毒的初免-加强免疫方案可在黑猩猩中诱导针对恶性疟原虫TRAP抗原的强烈细胞免疫反应。
Vaccine. 2001 Sep 14;19(32):4595-602. doi: 10.1016/s0264-410x(01)00260-2.
8
Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.基于恶性疟原虫顶端膜抗原1（PfAMA1）的DNA、蛋白质和重组改良安卡拉痘苗疫苗的初免-加强免疫方案在小鼠中诱导的免疫反应。
Vaccine. 2006 Sep 11;24(37-39):6187-98. doi: 10.1016/j.vaccine.2006.05.099. Epub 2006 Jun 12.
9
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.在 ChAd63 和 MVA 疫苗载体中评估恶性疟原虫血期抗原 AMA1 的安全性和免疫原性的 I 期临床研究。
PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.
10
Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.表达恶性疟原虫裂殖子表面蛋白 1 的重组病毒载体疫苗：疫苗诱导的红内期保护机制。
J Immunol. 2012 May 15;188(10):5041-53. doi: 10.4049/jimmunol.1101106. Epub 2012 Apr 13.
引用本文的文献
1
Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review.评估疫苗和药物疗效的人体疟疾子孢子挑战模型的可重复性：系统评价。
BMC Infect Dis. 2021 Dec 20;21(1):1274. doi: 10.1186/s12879-021-06953-4.
2
Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.黑猩猩腺病毒载体作为爆发性病原体的疫苗。
Hum Vaccin Immunother. 2017 Dec 2;13(12):3020-3032. doi: 10.1080/21645515.2017.1383575. Epub 2017 Oct 30.
3
Controlled Human Malaria Infection: Applications, Advances, and Challenges.人体疟疾感染控制：应用、进展与挑战
Infect Immun. 2017 Dec 19;86(1). doi: 10.1128/IAI.00479-17. Print 2018 Jan.
4
Recombinant modified vaccinia virus Ankara-based malaria vaccines.基于重组改良安卡拉痘苗病毒的疟疾疫苗。
Expert Rev Vaccines. 2016;15(1):91-103. doi: 10.1586/14760584.2016.1106319. Epub 2015 Oct 29.
5
The evolution of poxvirus vaccines.痘病毒疫苗的演变
Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726.
6
A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.一项Ia期研究，旨在评估新型疟疾疫苗候选物ChAd63 CS单独使用及与MVA CS联合使用时的安全性和免疫原性。
PLoS One. 2014 Dec 18;9(12):e115161. doi: 10.1371/journal.pone.0115161. eCollection 2014.
7
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.评估表达环子孢子蛋白和ME-TRAP的ChAd63-MVA载体疫苗对未感染疟疾个体的受控人类疟疾感染的疗效。
J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579. Epub 2014 Oct 21.
8
4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.4-1BBL增强了载体疫苗在小鼠中诱导的CD8 + T细胞反应，但未能提高恒河猴的免疫原性。
PLoS One. 2014 Aug 20;9(8):e105520. doi: 10.1371/journal.pone.0105520. eCollection 2014.
9
Induction of an Antibody Response against Plasmodium falciparum F2RIIEBA by Heterologous Prime-boost Immunisation.通过异源初免-加强免疫诱导针对恶性疟原虫F2RIIEBA的抗体反应。
Trop Life Sci Res. 2013 Aug;24(1):9-18.
10
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.确定参与候选疫苗早期临床试验的健康年轻成年人的医院实验室参考区间的有效性。
Hum Vaccin Immunother. 2013 Aug;9(8):1741-51. doi: 10.4161/hv.24998. Epub 2013 Jun 3.
本文引用的文献
1
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.重组鸡痘病毒株FP9和改良安卡拉痘苗病毒疫苗在非免疫志愿者中针对恶性疟原虫肝期疟疾的安全性。
Vaccine. 2006 Apr 5;24(15):3026-34. doi: 10.1016/j.vaccine.2005.10.058. Epub 2006 Feb 2.
2
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.RTS,S/AS02A疟疾疫苗预防莫桑比克儿童恶性疟原虫病的保护期：一项随机对照试验的单盲延长随访
Lancet. 2005 Dec 10;366(9502):2012-8. doi: 10.1016/S0140-6736(05)67669-6.
3
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.用于疟疾诊断的定量实时聚合酶链反应及其在疟疾疫苗临床试验中的应用。
Am J Trop Med Hyg. 2005 Jul;73(1):191-8.
4
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.使用表达重组HIV-1 nef的痘苗病毒安卡拉（MVA）对接受高效抗逆转录病毒治疗（HAART）的HIV-1感染患者进行治疗性疫苗接种：安全性、免疫原性及对治疗中断期间病毒载量的影响
Antivir Ther. 2005;10(2):285-300.
5
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.通过使用重组痘病毒FP9和改良安卡拉痘苗病毒，增强T细胞介导的对人类疟疾攻击的保护作用。
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41. doi: 10.1073/pnas.0406381102. Epub 2005 Mar 21.
6
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.通过对感染疟原虫子孢子的志愿者进行系列定量聚合酶链反应研究，计算肝脏与血液接种量、寄生虫生长率以及疟原虫感染前期疫苗效力。
J Infect Dis. 2005 Feb 15;191(4):619-26. doi: 10.1086/427243. Epub 2005 Jan 7.
7
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.在健康志愿者中使用DNA和病毒载体的各种异源初免-加强疫苗方案的差异免疫原性。
J Immunol. 2005 Jan 1;174(1):449-55. doi: 10.4049/jimmunol.174.1.449.
8
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.一项针对冈比亚成年人的DNA/MVA ME-TRAP预防疟疾感染的随机、双盲、对照疫苗效力试验。
PLoS Med. 2004 Nov;1(2):e33. doi: 10.1371/journal.pmed.0010033. Epub 2004 Oct 26.
9
Does malaria suffer from lack of memory?疟疾是否存在记忆缺失问题？
Immunol Rev. 2004 Oct;201:268-90. doi: 10.1111/j.0105-2896.2004.00181.x.
10
Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif.通过接种编码缺乏糖基磷脂酰肌醇（GPI）锚定基序的疟原虫环子孢子蛋白的重组腺病毒增强对疟疾的保护性免疫。
Vaccine. 2004 Sep 9;22(27-28):3575-84. doi: 10.1016/j.vaccine.2004.03.050.
Zotero 插件